Vitamin B6 belongs in a healthy diet. That does not make a high-dose capsule a harmless precaution. The important distinction is between meeting a nutritional need and taking extra B6 for an unproven benefit. For supplement users, nerve injury is a recognised concern, while the exact boundary between dose, duration, and individual susceptibility remains uncertain.
The benefit needs a name
A supplement deserves the same first question as a medicine: what outcome is it supposed to improve? “Supports the nervous system” is too broad to answer that. It could describe a nutrient’s normal biological role, correction of a deficiency, or treatment of a disease. Those are different claims, requiring different evidence.
The NIH consumer evidence summary reports that B6 supplementation does not appear to improve cognition or mood in healthy people or people with dementia. It also says studies have not established that B6 supplements prevent cancer or reduce deaths from it. Associations between blood levels and health outcomes therefore need care: they do not establish that adding a capsule will improve the outcome.
There are legitimate clinical uses. The same NIH summary describes B6 for nausea and vomiting in pregnancy under a doctor’s care. That is a defined indication with supervision, rather than a general invitation to take more. Pregnancy is a reason to discuss supplementation with a clinician, not to borrow a treatment dose from an article.
What the nerve-injury evidence establishes
In a 2023 systematic review in Nutrients, Raman Muhamad and colleagues evaluated 20 human studies concerning B6 and peripheral neuropathy. Higher B6 levels, commonly following supplement use, were associated with predominantly sensory nerve injury. Some patients reported improvement after pyridoxine was discontinued, but small samples and limited objective follow-up constrained the conclusions.
The review also examined B6 as a treatment for neuropathy. Studies reporting improvement generally used combinations of vitamins or other treatments, so the contribution of B6 alone could not be established. A combination product cannot demonstrate the effectiveness of each ingredient simply because symptoms improved during its use.
This is a safety signal with an imperfect evidence base. It does not support either extreme: that every B6 supplement causes injury, or that a vitamin cannot cause injury because the body needs it. The review’s limitations also matter when discussing recovery. Improvement in reported symptoms is not proof that every affected nerve has recovered, or that everyone follows the same course.
Three dose numbers that answer different questions
For adults aged 19–64, NHS guidance on B vitamins gives nutritional requirements of about 1.4 mg daily for men and 1.2 mg for women. It advises against more than 10 mg of B6 daily in supplements unless a doctor recommends it. A requirement describes nutritional need; the supplement advice addresses excessive intake. Neither number is a treatment plan.
The 2023 assessment in EFSA Journal established an adult tolerable upper intake level of 12 mg daily, including pregnancy and lactation. This concerns total intake from food and supplements. It is therefore not directly interchangeable with the NHS’s supplement-only advice.
EFSA used peripheral neuropathy as the critical adverse effect and applied an uncertainty factor to a reference point of 50 mg daily. The assessment explicitly recognised uncertainty about the lowest intake producing harm and the relationship between dose and time to symptoms. The resulting limit is a population risk-management value. It is not a target to aim for, or a guarantee that a particular person can take that amount indefinitely.
For context, the NIH health-professional fact sheet also lists the US adult upper limit of 100 mg daily and acknowledges EFSA’s lower value. The disagreement is a reason to read the underlying assessment, rather than select whichever ceiling accommodates a product.
The compound and the product are separate questions
B6 is a family of related compounds. Pyridoxine is widely used in supplements; pyridoxal-5-phosphate, often abbreviated PLP or P5P, is another form readers may encounter. A 2021 review in Advances in Nutrition examined how pyridoxine might damage sensory nerves, proposing interference with pyridoxal kinase and downstream signalling as a plausible mechanism. The authors emphasised that the mechanism remained unresolved.
A proposed mechanism cannot settle a product comparison. Calling a form “active” does not supply a long-term human safety trial, and a mechanistic argument about pyridoxine is insufficient evidence that another form is exempt from caution. The appropriate question is whether comparative clinical evidence establishes that exemption. A mechanistic review does not establish comparative long-term safety.
The product assessment can start more simply. Record the stated B6 form, the milligrams per serving, and how many servings are actually taken. If two hypothetical products provide 5 mg each per daily serving, they contribute 10 mg together. That arithmetic says nothing about benefit; it prevents a discussion of exposure from considering only one bottle. It also distinguishes the label’s claimed amount from a laboratory measurement of the contents.
Lower-dose reports require careful interpretation
Florence van Hunsel and colleagues examined 224 reports in the Dutch spontaneous reporting system in a 2025 study in Pharmacoepidemiology and Drug Safety. After a 2018 restriction on maximum supplement doses, the doses appearing in reports changed, but reports involving lower doses continued. The authors called for further investigation of the association.
These reports are useful for detecting possible harms, but they are not a controlled trial. Without a reliable denominator of exposed users, the report count cannot tell a reader their probability of developing neuropathy. A report also does not establish causation by itself. Alternative causes, incomplete exposure histories, and differences in reporting all complicate interpretation.
The responsible message is narrower than “low doses are dangerous”. Reports warrant investigation and undermine easy reassurance based solely on a modest-looking label. They cannot supply a precise minimum toxic dose, prove that every reported case was caused by B6, or establish that a person below a particular limit has no risk.
Symptoms and medicines change the discussion
The NHS overview of peripheral neuropathy identifies tingling, numbness, pain, balance difficulties, and weakness as possible symptoms. It advises seeing a GP for early symptoms. Diabetes is a common cause, and other causes include injury, certain medicines, and excessive alcohol use. Symptoms should therefore prompt assessment rather than a self-diagnosis of B6 toxicity.
Bring the supplement history into that assessment: product names, labels, servings, and duration. A clinician can consider the wider history and decide which examination or tests are appropriate. A blood result alone should not replace that evaluation.
Medication review matters too. The NIH health-professional fact sheet describes interactions involving certain antiepileptic medicines, cycloserine, and theophylline. At 200 mg daily, pyridoxine has been reported to reduce concentrations of phenytoin and phenobarbital; effects of lower doses are uncertain. These are clinician or pharmacist questions. Anyone receiving prescribed B6 should discuss concerns with the prescriber before changing the regimen.
What this means in practice
- Make a complete list of supplement products, B6 forms, milligrams per serving, actual servings, and duration. Include products taken for different purposes.
- Ask what specific benefit justifies each product. A normal biological role is not evidence that extra intake improves that outcome.
- Use the NHS’s 10 mg supplement advice as a reason to review an unsupervised higher intake with a pharmacist or GP, rather than as a dose recommendation.
- Seek medical assessment for new or persistent tingling, numbness, pain, weakness, or balance problems. Bring the product list; do not assume the cause.
- Discuss prescribed B6, pregnancy, and possible medicine interactions with the relevant clinician before making changes. An online safety limit cannot replace that review.
What we don’t know
We cannot give every reader a dependable dose-and-duration threshold for nerve injury. Comparative long-term safety evidence across forms remains insufficient for a blanket reassurance, and spontaneous reports cannot quantify individual risk. Nor does the treatment literature establish B6 alone as a general remedy for neuropathy. These gaps should remain visible whenever benefit and harm are discussed.
The useful question is specific: what is this product expected to do, at this dose and in this form, and what evidence justifies taking it?
Photo: Kaboompics.com on Pexels. Illustrative tablets; the image does not identify vitamin B6 products.
